These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37572120)

  • 1. Exploring the correlation between HER2 alterations and
    Ruan M; Chang C; Sun J; Liu L; Wang L; Lei B; Yan H; Zhang H; Xie W; Wang Y
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):14493-14507. PubMed ID: 37572120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of
    Lv Z; Fan J; Xu J; Wu F; Huang Q; Guo M; Liao T; Liu S; Lan X; Liao S; Geng W; Jin Y
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of FDG PET/CT, tumor markers and Ki-67 index with EGFR mutation or positive ALK expression in patients with non-small cell lung cancer.
    Wang HC; Wang ZM; Hu WD; Liang XQ; Cui LL
    Q J Nucl Med Mol Imaging; 2024 Sep; 68(3):169-175. PubMed ID: 39008330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between combining
    Ruan M; Liu L; Wang L; Lei B; Sun X; Chang C; Shen Y; Xie W
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1183-1197. PubMed ID: 31897590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of multiple metabolic and heterogeneity parameters of
    Shi A; Wang J; Wang Y; Guo G; Fan C; Liu J
    Ann Nucl Med; 2022 Apr; 36(4):393-400. PubMed ID: 35084711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
    Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
    Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma.
    Yanarateş A; Yazici B
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):3-8. PubMed ID: 31818695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cigarette smoking on metabolic activity of lung cancer on baseline
    Jiang M; Guo X; Zhang X; Gao Q; Mei W; Zhang J; Zheng J
    PeerJ; 2022; 10():e13352. PubMed ID: 35497180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis.
    Chen L; Zhou Y; Tang X; Yang C; Tian Y; Xie R; Chen T; Yang J; Jing M; Chen F; Wang C; Sun H; Huang Y
    Int J Oncol; 2019 Jan; 54(1):370-380. PubMed ID: 30431083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnostic and predictive efficacy of
    Guo Y; Zhu H; Yao Z; Liu F; Yang D
    Eur J Radiol; 2021 Aug; 141():109792. PubMed ID: 34062472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of interim
    Shao D; Cheng Y; Yuan ZS; Jiang BY; Wang SX
    Lung Cancer; 2020 Nov; 149():137-143. PubMed ID: 33011375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic tumor volume derived from
    Ding C; Mao X; Li N; Huang M; Huang Z; Bao W; Li H; Fan J
    Hell J Nucl Med; 2022; 25(1):63-70. PubMed ID: 35503557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insight on the correlation of metabolic status on
    Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiogenomic Models Using Machine Learning Techniques to Predict EGFR Mutations in Non-Small Cell Lung Cancer.
    Nair JKR; Saeed UA; McDougall CC; Sabri A; Kovacina B; Raidu BVS; Khokhar RA; Probst S; Hirsh V; Chankowsky J; Van Kempen LC; Taylor J
    Can Assoc Radiol J; 2021 Feb; 72(1):109-119. PubMed ID: 32063026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential of
    Wang L; Ruan M; Lei B; Yan H; Sun X; Chang C; Liu L; Xie W
    Lung Cancer; 2020 Dec; 150():44-52. PubMed ID: 33065462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The correlation between PD-L1 expression and metabolic parameters of
    Xu X; Li J; Yang Y; Sang S; Deng S
    Clin Imaging; 2022 Sep; 89():120-127. PubMed ID: 35797878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.